A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
NCT03050190
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
200
Enrollment
OTHER
Sponsor class
Conditions
B-cell Malignancies
Interventions
GENETIC:
Therapeutic 4SCAR19 cells
Sponsor
Shenzhen Geno-Immune Medical Institute